Liposome as a drug carrier

Mulla, Tabasum Siraj; Thorat, Monika Sanjay; Rayate, Yogita; Nitalikar, Manoj M.

doi:10.5958/2231-5659.2019.00021.3

Cited by 8 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or Lipid film hydration (Mulla, Thorat, Rayate, & Nitalikar, 2019) In this method, lipids are caste like stacks of film from its organic solution using a handshaking or with the use of the flash rotary evaporator under reduced pressure may. When lipids are hydrated, they possess swelling properties and peel off from the circular bottom flask resulting in the formation of MLVs and LUVs, respectively.…”

Section: Handshaking or Non-hand Shankingmentioning

confidence: 99%

“…V. Micro-emulsification (Mulla et al, 2019) The "Micro Fluidizer" turns concentrated lipid dispersion into micro MLVs. Lipids can be added to fluidizers in the form of a slurry (which contains un-hydrated lipids in an organic medium) or as a dispersion of big MLVs.…”

Section: Handshaking or Non-hand Shankingmentioning

confidence: 99%

“…After a single pass, vesicles are shrunk to between 0.1 and 0.2um in diameter. (Mulla et al, 2019) It works with both LUVs and MLVs. This process produces liposomes called membrane filter extrusion liposomes.…”

Section: Handshaking or Non-hand Shankingmentioning

confidence: 99%

See 2 more Smart Citations

Vesicular drug delivery systems for the fungal infections’ treatment through topical application-a systemic review

Tushar Rukari,

Prashant Pingale,

Chandrashekhar Upasani

2023

JCST

View full text Add to dashboard Cite

In this systemic review, we tried to explore and summarize the Vesicular Drug Delivery Systems (VDDSs) which can exclusively used for topical applications in the treatment of fungal infections. The specific algorithm is developed for this systemic review, exclusion criteria for the review were set and results were excluded which were meets the exclusion criteria. To build a review, Google Scholar® and PubMed® are two databases that are targeted so that we can collect the number of freely available full-text articles and can minimize the risk of bias (unavailability of full-text articles, for this study). By adopting the algorithm, searched articles were studied thoroughly and we found that thirteen types of VDDS were used by the researchers to treat skin infections caused by fungi in the last five years. From this current systemic review, we found a numbers of VDDSs are available for skin fungal infection, but all are not suitable for topical applications because of some drawbacks associated with some VDDS such as instability (Emulsomes), high cost of manufacturing (Sphingosomes), low transfer efficiency (Aquasomes), etc. As per the data analysed, we can say that; Liposomes, Ethosomes, Niosomes, Bilosomes, Cubosomes, and Ufasomes are the choices of researchers as VDDS in the therapy of different fungal diseases. Upcoming researchers can focus on these VDDSs in the treatment of infections spread on the skin by the fungi.

show abstract

Section: Handshaking or Non-hand Shankingmentioning

confidence: 99%

Section: Handshaking or Non-hand Shankingmentioning

confidence: 99%

See 1 more Smart Citation

Vesicular drug delivery systems for the fungal infections’ treatment through topical application-a systemic review

Tushar Rukari,

Prashant Pingale,

Chandrashekhar Upasani

2023

JCST

View full text Add to dashboard Cite

show abstract

“…Thus, this impact could be applied via the entrapment of a lower pH environment into liposomes and the vesicle suspension in a neutral-pH environment consisting of the drugs. 132…”

Section: Challengesmentioning

confidence: 99%

“…Such a technique entailed the use of an uncharged drug with the ability to easily cross from lipid bilayer in an uncharged form; however, it modified the charged species once inside the liposome (namely, the drug could not escape the inside part of the liposomes in the charged form). Thus, this impact could be applied via the entrapment of a lower pH environment into liposomes and the vesicle suspension in a neutral‐pH environment consisting of the drugs 132 …”

Section: Challengesmentioning

confidence: 99%

Liposomes: Ideal drug delivery systems in breast cancer

Forouhari

Beygi

Mansoori

et al. 2021

Biotech and App Biochem

View full text Add to dashboard Cite

Breast cancer (BC) has been recognized as the most common type of cancer in females across the world, accounting for 12% of each cancer case. In this sense, better diagnosis and screening have been thus far proven to contribute to higher survival rates. Moreover, traditional (or standard) chemotherapy is still known as one of the several prominent therapeutic options available, though it suffers from unsuitable cell selectivity, severe consequences, as well as resistance. In this regard, nanobased drug delivery systems (DDSs) are likely to provide promising grounds for BC treatment. Liposomes are accordingly effective nanosystems, having the benefits of multiple formulations verified to treat different diseases. Such systems possess specific features, including smaller size, biodegradability, hydrophobic/hydrophilic characteristics, biocompatibility, lower toxicity, as well as immunogenicity, which can all lead to considerable efficacy in treating various types of cancer. As chemotherapy uses drugs to target tumors, generates higher drug concentrations in tumors, which can provide for their slow release, and enhances drug stability, it can be improved via liposomes in DDSs for BC treatment. Therefore, the present study aims to review the existing issues regarding BC treatment and discuss liposome‐based targeting in order to overcome barriers to conventional drug therapy.

show abstract